Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.


Journal

Current protocols
ISSN: 2691-1299
Titre abrégé: Curr Protoc
Pays: United States
ID NLM: 101773894

Informations de publication

Date de publication:
Aug 2022
Historique:
entrez: 11 8 2022
pubmed: 12 8 2022
medline: 16 8 2022
Statut: ppublish

Résumé

The CRISPR system is an adaptive defense mechanism used by bacteria and archaea against viruses and plasmids. The discovery of the CRISPR-associated protein Cas9 and its RNA-guided cleavage mechanism marked the beginning of a new era in genomic engineering by enabling the editing of a target region in the genome. Gene-edited cells or mice can be used as models for understanding human diseases. Given its high impact in functional genomic experiments on different model systems, several CRISPR/Cas9 protocols have been generated in the past years. The technique uses a straightforward "cut and stitch" mechanism, but requires an accurate step-by-step design. One of the key points is the use of an efficient programmable guide RNA to increase the rate of success in obtaining gene-specific edited clones. Here, we describe an efficient editing protocol using a ribonucleotide protein (RNP) complex for homology-directed repair (HDR)-based correction of a point mutation in an induced pluripotent stem cell (iPSC) line generated from a 14-year-old patient with severe early-onset obesity carrying a de novo variant of ARNT2. The resulting isogenic iPSC line, named CUIMCi003-A-1, has a normal karyotype, expresses stemness markers, and can be differentiated into progenies from all three germ layers. We provide a detailed workflow for designing a single guide RNA and donor DNA, and for isolating clonal human iPSCs edited with the desired modification. This article also focuses on parameters to consider when selecting reagents for CRISPR/Cas9 gene editing after testing their efficiency with in silico tools. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Design of sgRNAs and PCR primers Basic Protocol 2: Testing the efficiency of sgRNAs Basic Protocol 3: Design of template or donor DNA Basic Protocol 4: Targeted gene editing Basic Protocol 5: Selection of positive clones Basic Protocol 6: Freezing, thawing, and expansion of cells Basic Protocol 7: Characterization of edited cell lines.

Identifiants

pubmed: 35950852
doi: 10.1002/cpz1.519
pmc: PMC9377717
mid: NIHMS1822542
doi:

Substances chimiques

RNA, Guide 0
DNA 9007-49-2

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e519

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK026687
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022 The Authors. Current Protocols published by Wiley Periodicals LLC.

Références

Stem Cell Res. 2021 Jul;54:102432
pubmed: 34214899
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
Genome Res. 2014 Jun;24(6):1012-9
pubmed: 24696461
Nature. 2014 Mar 6;507(7490):62-7
pubmed: 24476820
Nat Biotechnol. 2014 Jul;32(7):670-6
pubmed: 24752079
Nat Methods. 2013 Oct;10(10):957-63
pubmed: 24076990
Cell. 2014 Feb 27;156(5):935-49
pubmed: 24529477
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W401-7
pubmed: 24861617
J Biotechnol. 2015 Aug 20;208:44-53
pubmed: 26003884
Mol Ther Nucleic Acids. 2019 Jun 7;16:73-81
pubmed: 30852378
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Protein Cell. 2022 May;13(5):316-335
pubmed: 33945139
Nucleic Acids Res. 2004 Jul 13;32(12):3683-8
pubmed: 15252152
Nat Biotechnol. 2013 Sep;31(9):839-43
pubmed: 23934178
Nat Rev Genet. 2010 Sep;11(9):636-46
pubmed: 20717154
Nature. 2008 Jan 10;451(7175):141-6
pubmed: 18157115
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Cell Stem Cell. 2007 Jun 7;1(1):55-70
pubmed: 18371336
Methods Enzymol. 2019;616:241-263
pubmed: 30691645
Nature. 2007 Jul 19;448(7151):318-24
pubmed: 17554336
Nat Biotechnol. 2014 Mar;32(3):279-284
pubmed: 24463574
Nucleic Acids Res. 2020 May 21;48(9):5037-5053
pubmed: 32315032
Elife. 2014 Dec 15;3:e04766
pubmed: 25497837
Elife. 2013 Jan 29;2:e00471
pubmed: 23386978

Auteurs

Achchhe Patel (A)

Columbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.

Grazia Iannello (G)

Columbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.

Alejandro Garcia Diaz (AG)

Spanish National Cancer Research Center, Madrid, Spain.

Dario Sirabella (D)

Columbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.

Vidhu Thaker (V)

Division of Molecular Genetics, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York.

Barbara Corneo (B)

Columbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH